|
Outcome of the First Review of Country Proposals
to the Global Alliance for Vaccines and Immunization and the Vaccine Fund
The first call for proposals
to GAVI and the Vaccine Fund was issued in May 2000 to the
74 eligible countries those with gross national product
(GNP) of less than US$1000 per capita. Of the twenty-four
proposals received by the end of June, an independent review
committee found that 13 countries were ready to receive
vaccines and/or direct financial support, but additional
information was needed to finalize the awards. This information
has been received from all countries.
The GAVI Board has now
endorsed the recommendations of the independent committee
and the Vaccine Fund board has agreed to support the 13 proposals.
Final announcement of
the awards was made via letters to the 13 health ministries
and an international news release on 20 September. Other
eligible countries are asked to submit proposals when they
are ready, for review during the next scheduled rounds in
October 2000 and thereafter throughout 2001 and early 2002.
The funding from the immunization services
sub-account will start to be disbursed in October. The support
from the new and under-used vaccines sub-account will result
in a tendering procedure by the UNICEF Supply division in
October 2000, with vaccines and supplies to be delivered
in the first half of 2001.
Below is a table summarizing
the decision to support the first round of countries in the form
of vaccines and/or funding for strengthening of immunization services.
Calculated
support to first 13 countries for the year 2001
(amounts in US Dollars)
Country
|
Birth cohort (2000)
|
Immunization services support(1)
|
New and under-used vaccines plans
|
Estimated value of vaccine support(2)
|
Estimated total value of 2001 award
|
Cambodia
|
355,000
|
|
hepB - phased
|
103,000
|
103,000
|
Côte dIvoire
|
546,000
|
513,000
|
|
|
513,000
|
Ghana
|
736,000
|
264,500
|
hepB natl
yellow fever natl
|
3,700,000
|
3,964,500
|
Guyana
|
17,000
|
|
hepB and Hib natl
|
280,000
|
280,000
|
Kenya
|
994,000
|
644,500
|
hepB and Hib natl
yellow fever 4 districts
|
6,500,000
|
7,144,500
|
Kyrgyz Republic
|
114,000
|
|
hepB natl (incl. birth
dose)
|
351,000
|
351,000
|
Lao PDR
|
207,000
|
|
hepB - phased
|
293,000
|
293,000
|
Madagascar
|
608,000
|
233,500
|
hepB natl
|
2,500,000
|
2,733,500
|
Malawi
|
505,000
|
|
hepB and Hib natl
|
6,500,000
|
6,500,000
|
Mali
|
515,000
|
429,000
|
|
|
429,000
|
Mozambique
|
832,000
|
231,000
|
HepB natl
|
1,500,000
|
1,731,000
|
Rwanda
|
309,000
|
454,000
|
|
|
454,000
|
Tanzania
|
1,347,000
|
607,000
|
HepB natl
|
5,500,000
|
6,107,000
|
TOTAL
|
|
$3,376,500
|
|
$27,227,000
|
$30,603,500
|
1) Includes 50% of two-year
initial investment commitment, with second 50% instalment to be
paid in October 2001.
2) Cost estimates based
upon current vaccine prices; final cost will result from the tendering
procedure. Calculation includes 2001 dosage requirements including
buffer stock and wastage calculations, and appropriate quantities
of auto-destruct syringes and safety boxes.
|